Effects of probiotic Lactobacillus rhamnosus GG and Propionibacterium freudenreichii ssp. shermanii JS supplementation on intestinal and systemic markers of inflammation in ApoE*3Leiden mice consuming a high-fat diet

British Journal of Nutrition

Volumn 110, Issue 1, 2013, Pages 77-85

  Oksaharju, Anna ^a   Kooistra, Teake ^b   Kleemann, Robert ^b   Van Duyvenvoorde, Wim ^b   Miettinen, Minja ^c   Lappalainen, Jani ^a   Lindstedt, Ken A ^d   Kovanen, Petri T ^a   Korpela, Riitta ^e   Kekkonen, Riina A ^c  

^a WIHURI RESEARCH INSTITUTE   (Finland)

^b TNO   (Netherlands)

^c VALIO LTD   (Finland)

^d ORION CORPORATION   (Finland)

^e UNIVERSITY OF HELSINKI   (Finland)

Author keywords

3Leiden mice; ApoE; Inflammation; Mast cells; Probiotic bacteria

Indexed keywords

ADIPONECTIN; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; BIOLOGICAL MARKER; CHOLESTEROL; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FENOFIBRATE; FIBRINOGEN; INTERLEUKIN 10; PROBIOTIC AGENT; SERUM AMYLOID A; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ADIPOSE TISSUE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL COUNT; CONTROLLED STUDY; DIET SUPPLEMENTATION; ENZYME ACTIVATION; IMMUNOREACTIVITY; INTESTINE; LACTOBACILLUS RHAMNOSUS; LIPID DIET; LIPID METABOLISM; LIVER CELL; MALE; MAST CELL; MOUSE; NONHUMAN; PROPIONIBACTERIUM FREUDENREICHII SHERMANII; PROTEIN BLOOD LEVEL;

ADIPOSE TISSUE; ALANINE TRANSAMINASE; ANIMALS; DIET, HIGH-FAT; GONADS; INFLAMMATION; INFLAMMATION MEDIATORS; INTERLEUKIN-10; INTESTINAL MUCOSA; LACTOBACILLUS RHAMNOSUS; LIPID METABOLISM; LIVER; MALE; MAST CELLS; METAGENOME; MICE; MICE, INBRED STRAINS; PROBIOTICS; PROPIONIBACTERIUM; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR CELL ADHESION MOLECULE-1;

LACTOBACILLUS RHAMNOSUS; MUS; PROPIONIBACTERIUM FREUDENREICHII;

EID: 84879199341     PISSN: 00071145     EISSN: 14752662     Source Type: Journal    
DOI: 10.1017/S0007114512004801     Document Type: Article

References (63)

1. Cani PD & Delzenne NM (2009) The role of the gut microbiota in energy metabolism and metabolic disease. Curr Pharm Des 15, 1546-1558.
2. Hotamisligil GS (2006) Inflammation and metabolic disorders. Nature 444, 860-867.
3. Cai D, Yuan M, Frantz DF, et al. (2005) Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nat Med 11, 183-190.
4. Hotamisligil GS, Shargill NS & Spiegelman BM (1993) Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 259, 87-91.
5. Kappelle PJ, Bijzet J, Hazenberg BP, et al. (2011) Lower serum paraoxonase-1 activity is related to higher serum amyloid a levels in metabolic syndrome. Arch Med Res 42, 219-225.
6. Ding S, Chi MM, Scull BP, et al. (2010) High-fat diet: bacteria interactions promote intestinal inflammation which precedes and correlates with obesity and insulin resistance in mouse. PLoS One 5, e12191.
7. Cani PD, Bibiloni R, Knauf C, et al. (2008) Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes 57, 1470-1481.
8. Metz M, Grimbaldeston MA, Nakae S, et al. (2007) Mast cells in the promotion and limitation of chronic inflammation. Immunol Rev 217, 304-328.
9. Bischoff SC (2009) Physiological and pathophysiological functions of intestinal mast cells. Semin Immunopathol 31, 185-205.
10. Kovanen PT (2007) Mast cells: multipotent local effector cells in atherothrombosis. Immunol Rev 217, 105-122.
11. Liu J, Divoux A, Sun J, et al. (2009) Genetic deficiency and pharmacological stabilization of mast cells reduce dietinduced obesity and diabetes in mice. Nat Med 15, 940-945.
12. Galli SJ, Grimbaldeston M & Tsai M (2008) Immunomodulatory mast cells: negative, as well as positive, regulators of immunity. Nat Rev Immunol 8, 478-486.
13. Tlaskalova-Hogenova H, Stepankova R, Kozakova H, et al. (2011) The role of gut microbiota (commensal bacteria) and the mucosal barrier in the pathogenesis of inflammatory and autoimmune diseases and cancer: contribution of germfree and gnotobiotic animal models of human diseases. Cell Mol Immunol 8, 110-120.
14. Turnbaugh PJ, Ridaura VK, Faith JJ, et al. (2009) The effect of diet on the human gut microbiome: a metagenomic analysis in humanized gnotobiotic mice. Sci Transl Med 1, 6ra14.
15. Collins MD & Gibson GR (1999) Probiotics, prebiotics, and synbiotics: approaches for modulating the microbial ecology of the gut. Am J Clin Nutr 69, 1052S-1057S.
16. Fooks LJ & Gibson GR (2002) Probiotics as modulators of the gut flora. Br J Nutr 88, Suppl. 1, S39-S49.
17. FAO/WHO (2002) Guides for the Evaluation of Probiotics in Food. London/Ontario: Food and Agriculture Organization of the United Nations and World Health Organization.
18. Miettinen M, Veckman V, Latvala S, et al. (2008) Live Lactobacillus rhamnosus and Streptococcus pyogenes differentially regulate Toll-like receptor (TLR) gene expression in human primary macrophages. J Leukoc Biol 84, 1092-1100.
19. Parvez S, Malik KA, Ah Kang S, et al. (2006) Probiotics and their fermented food products are beneficial for health. J Appl Microbiol 100, 1171-1185.
20. Kekkonen RA, Kajasto E, Miettinen M, et al. (2008) Probiotic Leuconostoc mesenteroides ssp. cremoris and Streptococcus thermophilus induce IL-12 and IFN-gamma production. World J Gastroenterol 14, 1192-1203.
21. Kekkonen RA, Lummela N, Karjalainen H, et al. (2008) Probiotic intervention has strain-specific anti-inflammatory effects in healthy adults. World J Gastroenterol 14, 2029-2036.
22. Saini R, Saini S & Sharma S (2010) Potential of probiotics in controlling cardiovascular diseases. J Cardiovasc Dis Res 1, 213-214.
23. Amar J, Chabo C, Waget A, et al. (2011) Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 3, 559-572.
24. Lee do K, Park SY, Jang S, et al. (2011) The combination of mixed lactic acid bacteria and dietary fiber lowers serum cholesterol levels and fecal harmful enzyme activities in rats. Arch Pharm Res 34, 23-29.
25. Zadelaar S, Kleemann R, Verschuren L, et al. (2007) Mouse models for atherosclerosis and pharmaceutical modifiers. Arterioscler Thromb Vasc Biol 27, 1706-1721.
26. Kooistra T, Verschuren L, de Vries-van der Weij J, et al. (2006) Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol. Arterioscler Thromb Vasc Biol 26, 2322-2330.
27. Oksaharju A, Lappalainen J, Tuomainen AM, et al. (2009) Pro-atherogenic lung and oral pathogens induce an inflammatory response in human and mouse mast cells. J Cell Mol Med 13, 103-113.
28. Fujiyama Y, Hokari R, Miura S, et al. (2007) Butter feeding enhances TNF-alpha production from macrophages and lymphocyte adherence in murine small intestinal microvessels. J Gastroenterol Hepatol 22, 1838-1845.
29. Ji Y, Sakata Y & Tso P (2011) Nutrient-induced inflammation in the intestine. Curr Opin Clin Nutr Metab Care 14, 315-321.
30. De Winter BY, van den Wijngaard RM & de Jonge WJ (2012) Intestinal mast cells in gut inflammation and motility disturbances. Biochim Biophys Acta 1822, 66-73.
31. Sawada J, Morita H, Tanaka A, et al. (2007) Ingestion of heattreated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. Clin Exp Allergy 37, 296-303.
32. Tobita K, Yanaka H & Otani H (2010) Anti-allergic effects of Lactobacillus crispatus KT-11 strain on ovalbumin-sensitized BALB/c mice. Anim Sci J 81, 699-705.
33. Huang J, Zhong Y, Cai W, et al. (2010) The effects of probiotics supplementation timing on an ovalbumin-sensitized rat model. FEMS Immunol Med Microbiol 60, 132-141.
34. Won TJ, Kim B, Lim YT, et al. (2011) Oral administration of Lactobacillus strains from Kimchi inhibits atopic dermatitis in NC/Nga mice. J Appl Microbiol 110, 1195-1202.
35. Senol A, Isler M, Karahan AG, et al. (2011) Effect of probiotics on aspirin-induced gastric mucosal lesions. Turk J Gastroenterol 22, 18-26.
36. Okon K & Stachura J (2007) Increased mast cell density in renal interstitium is correlated with relative interstitial volume, serum creatinine and urea especially in diabetic nephropathy but also in primary glomerulonephritis. Pol J Pathol 58, 193-197.
37. Atkinson JB, Harlan CW, Harlan GC, et al. (1994) The association of mast cells and atherosclerosis: a morphologic study of early atherosclerotic lesions in young people. Hum Pathol 25, 154-159.
38. Barbara G, Stanghellini V, De Giorgio R, et al. (2004) Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 126, 693-702.
39. Nishida Y, Murase K, Isomoto H, et al. (2002) Different distribution of mast cells and macrophages in colonic mucosa of patients with collagenous colitis and inflammatory bowel disease. Hepatogastroenterology 49, 678-682.
40. Finamore A, Roselli M, Britti MS, et al. (2012) Lactobacillus rhamnosus GG and Bifidobacterium animalis MB5 induce intestinal but not systemic antigen-specific hyporesponsiveness in ovalbumin-immunized rats. J Nutr 142, 375-385.
41. Oksaharju A, Kankainen M, Kekkonen RA, et al. (2011) Probiotic Lactobacillus rhamnosus downregulates FCER1 and HRH4 expression in human mast cells. World J Gastroenterol 17, 750-759.
42. Calder PC, Ahluwalia N, Brouns F, et al. (2011) Dietary factors and low-grade inflammation in relation to overweight and obesity. Br J Nutr 106, S5-S78.
43. Kamada N, Inoue N, Hisamatsu T, et al. (2005) Nonpathogenic Escherichia coli strain Nissle1917 prevents murine acute and chronic colitis. Inflamm Bowel Dis 11, 455-463.
44. Angulo S, Llopis M, Antolin M, et al. (2006) Lactobacillus casei prevents the upregulation of ICAM-1 expression and leukocyte recruitment in experimental colitis. Am J Physiol Gastrointest Liver Physiol 291, G1155-G1162.
45. Heikkilä HM, Trosien J, Metso J, et al. (2010) Mast cells promote atherosclerosis by inducing both an atherogenic lipid profile and vascular inflammation. J Cell Biochem 109, 615-623.
46. Yamashita M (2008) PPARalpha/gamma-independent effects of PPARalpha/gamma ligands on cysteinyl leukotriene production in mast cells. PPAR Res 2008, 293538.
47. Haro C, Zelaya H, Lazarte S, et al. (2009) Lactobacillus casei: influence on the innate immune response and haemostatic alterations in a liver-injury model. Can J Microbiol 55, 648-656.
48. Davalos D & Akassoglou K (2012) Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol 34, 43-62.
49. Kotronen A & Yki-Jarvinen H (2008) Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol 28, 27-38.
50. Li Z, Yang S, Lin H, et al. (2003) Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 37, 343-350.
51. Angelakis E, Bastelica D, Ben Amara A, et al. (2012) An evaluation of the effects of Lactobacillus ingluviei on body weight, the intestinal microbiome and metabolism in mice. Microb Pathog 52, 61-68.
52. Ouchi N, Kihara S, Funahashi T, et al. (2003) Obesity, adiponectin and vascular inflammatory disease. Curr Opin Lipidol 14, 561-566.
53. Flachs P, Mohamed-Ali V, Horakova O, et al. (2006) Polyunsaturated fatty acids of marine origin induce adiponectin in mice fed a high-fat diet. Diabetologia 49, 394-397.
54. Takemura N, Okubo T & Sonoyama K (2010) Lactobacillus plantarum strain no. 14 reduces adipocyte size in mice fed high-fat diet. Exp Biol Med (Maywood) 235, 849-856.
55. Mencarelli A, Distrutti E, Renga B, et al. (2011) Probiotics modulate intestinal expression of nuclear receptor and provide counter-regulatory signals to inflammation-driven adipose tissue activation. PLoS One 6, e22978.
56. Hatakka K, Mutanen M, Holma R, et al. (2008) Lactobacillus rhamnosus LC705 together with Propionibacterium freudenreichii ssp. shermanii JS administered in capsules is ineffective in lowering serum lipids. J Am Coll Nutr 27, 441-447.
57. Simons LA, Amansec SG & Conway P (2006) Effect of Lactobacillus fermentum on serum lipids in subjects with elevated serum cholesterol. Nutr Metab Cardiovasc Dis 16, 531-535.
58. Nguyen TD, Kang JH & Lee MS (2007) Characterization of Lactobacillus plantarum PH04, a potential probiotic bacterium with cholesterol-lowering effects. Int J Food Microbiol 113, 358-361.
59. Fukushima M, Yamada A, Endo T, et al. (1999) Effects of a mixture of organisms, Lactobacillus acidophilus or Streptococcus faecalis on delta6-desaturase activity in the livers of rats fed a fat-and cholesterol-enriched diet. Nutrition 15, 373-378.
60. Anderson JW & Gilliland SE (1999) Effect of fermented milk (yogurt) containing Lactobacillus acidophilus L1 on serum cholesterol in hypercholesterolemic humans. J Am Coll Nutr 18, 43-50.
61. Watts GF & Dimmitt SB (1999) Fibrates, dyslipoproteinaemia and cardiovascular disease. Curr Opin Lipidol 10, 561-574.
62. van Vlijmen BJ, van den Maagdenberg AM, Gijbels MJ, et al. (1994) Diet-induced hyperlipoproteinemia and atherosclerosis in apolipoprotein E3-Leiden transgenic mice. J Clin Invest 93, 1403-1410.
63. Wielinga PY, Yakala GK, Heeringa P, et al. (2011) Beneficial effects of alternate dietary regimen on liver inflammation, atherosclerosis and renal activation. PLoS One 6, e18432.